FY2024 EPS Estimates for BioNTech Decreased by Analyst

BioNTech SE (NASDAQ:BNTX) – Equities research analysts at Leerink Partnrs reduced their FY2024 earnings per share (EPS) estimates for BioNTech in a research note issued to investors on Wednesday, November 13th. Leerink Partnrs analyst D. Graybosch now anticipates that the company will earn ($3.79) per share for the year, down from their previous forecast of ($1.84). The consensus estimate for BioNTech’s current full-year earnings is ($3.68) per share. Leerink Partnrs also issued estimates for BioNTech’s Q4 2024 earnings at $0.42 EPS, Q1 2025 earnings at ($1.81) EPS, Q2 2025 earnings at ($2.30) EPS, Q3 2025 earnings at $2.20 EPS, Q4 2025 earnings at $1.85 EPS, FY2025 earnings at ($0.07) EPS, FY2026 earnings at ($0.41) EPS, FY2027 earnings at ($2.04) EPS and FY2028 earnings at ($1.09) EPS.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. During the same quarter in the prior year, the firm posted $0.73 earnings per share. The firm’s revenue was up 38.9% compared to the same quarter last year.

BNTX has been the subject of a number of other research reports. Bank of America increased their target price on shares of BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a research report on Monday, September 16th. Canaccord Genuity Group reissued a “buy” rating and set a $171.00 target price on shares of BioNTech in a research report on Thursday, November 14th. Berenberg Bank initiated coverage on shares of BioNTech in a research report on Tuesday. They set a “buy” rating and a $130.00 target price for the company. Deutsche Bank Aktiengesellschaft increased their target price on shares of BioNTech from $95.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday, September 19th. Finally, Jefferies Financial Group raised shares of BioNTech from a “hold” rating to a “buy” rating and increased their target price for the company from $96.00 to $150.00 in a research report on Tuesday, September 17th. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $138.79.

BioNTech Stock Performance

NASDAQ:BNTX opened at $106.40 on Monday. The company has a market capitalization of $25.51 billion, a PE ratio of -50.67 and a beta of 0.26. The company has a 50 day simple moving average of $113.68 and a two-hundred day simple moving average of $97.45. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. BioNTech has a fifty-two week low of $76.53 and a fifty-two week high of $131.49.

Hedge Funds Weigh In On BioNTech

A number of large investors have recently modified their holdings of the company. GAMMA Investing LLC lifted its holdings in shares of BioNTech by 21.7% in the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock worth $74,000 after purchasing an additional 111 shares in the last quarter. Covestor Ltd lifted its holdings in shares of BioNTech by 47.2% in the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after purchasing an additional 133 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in shares of BioNTech by 2.3% in the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 9,800 shares of the company’s stock worth $904,000 after purchasing an additional 223 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of BioNTech by 106.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after purchasing an additional 252 shares in the last quarter. Finally, Capital International Sarl lifted its holdings in shares of BioNTech by 1.3% in the 1st quarter. Capital International Sarl now owns 24,058 shares of the company’s stock worth $2,219,000 after purchasing an additional 310 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.